Please login to the form below

Not currently logged in
Email:
Password:

Non-24

This page shows the latest Non-24 news and features for those working in and with pharma, biotech and healthcare.

Generic Copaxone launches in US

Generic Copaxone launches in US

In a statement, Novartis said that Sandoz will offer "financial assistance to qualified patients, personalised injection training and 24-hour access to nurses for non-clinical questions" as part of the

Latest news

  • BMS' Opdivo backed as melanoma therapy in EU BMS' Opdivo backed as melanoma therapy in EU

    FDA approval as a second-line non-small cell lung cancer (NSCLC) therapy - a much larger market opportunity - in March. ... Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally

  • Running medical meetings Running medical meetings

    The sensitivities of the 'world' sector manifest in secretive meetings, 24-hour emails, decisions and non-decisions, last minute changes and demands, security focus, approvals… and the list goes on.

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind ... Non-24 affects people who are completely blind as light does

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... As a result, they can "fully enjoy the opportunities

  • Study suggests bias in industry research

    A new study in Annals of Internal Medicine suggests that drug studies funded by industry are significantly more likely to have favourable outcomes than those funded by the government or ... About 56 per cent of the trials funded by non-profits were

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics